Loading…

Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination

Development of T cell-directed immune checkpoint inhibitors (ICI) has revolutionized metastatic melanoma (MM) therapy, but 36 and >18 months, respectively). In addition, two patients had partial responses (PR), one still ongoing (>42 months) with only a small bone-lesion remaining, and one of...

Full description

Saved in:
Bibliographic Details
Published in:Oncoimmunology 2020-01, Vol.9 (1), p.1792058
Main Authors: Lövgren, Tanja, Wolodarski, Maria, Wickström, Stina, Edbäck, Ulrika, Wallin, Mette, Martell, Eva, Markland, Katrin, Blomberg, Pontus, Nyström, Maria, Lundqvist, Andreas, Jacobsson, Hans, Ullenhag, Gustav, Ljungman, Per, Hansson, Johan, Masucci, Giuseppe, Tell, Roger, Poschke, Isabel, Adamson, Lars, Mattsson, Jonas, Kiessling, Rolf
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Development of T cell-directed immune checkpoint inhibitors (ICI) has revolutionized metastatic melanoma (MM) therapy, but 36 and >18 months, respectively). In addition, two patients had partial responses (PR), one still ongoing (>42 months) with only a small bone-lesion remaining, and one of short duration (
ISSN:2162-4011
2162-402X
2162-402X
DOI:10.1080/2162402X.2020.1792058